<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The presence of <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> (LA) and anticardiolipin antibodies (ACA) are associated with recurring pregnancy loss </plain></SENT>
<SENT sid="1" pm="."><plain>Of 387 consecutive patients investigated at a Recurring <z:e sem="disease" ids="C0000786" disease_type="Disease or Syndrome" abbrv="">Miscarriage</z:e> Clinic over a three year period, 63 (16%) were positive for LA and ACA or both </plain></SENT>
<SENT sid="2" pm="."><plain>Fifty-nine patients by definition were classified as having <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> and four also had <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE) </plain></SENT>
<SENT sid="3" pm="."><plain>Fifty-three subsequent pregnancies occurred in 63 patients and of these 37 ended in a live birth giving an overall livebirth rate of 70% </plain></SENT>
<SENT sid="4" pm="."><plain>Treatment included low dose aspirin alone in 37 pregnancies and low dose aspirin and low molecular weight <z:chebi fb="5" ids="28304">heparin</z:chebi> (LMWH) in 16 pregnancies </plain></SENT>
<SENT sid="5" pm="."><plain>The decision for treatment was made empirically on past obstetric history and level of LA and ACA, and past history of venous <z:hpo ids='HP_0001907'>thromboembolic disease</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Obstetric outcome was worst in the group who were positive for both LA and ACA, with a success rate of 53%, compared to 72 or 81% in the single parameter groups </plain></SENT>
<SENT sid="7" pm="."><plain>Complications in the 37 successful pregnancies included eight Caesarean sections, four cases of intra-uterine growth restriction, one case of pregnancy induced proteinuric <z:hpo ids='HP_0000822'>hypertension</z:hpo>, one <z:hpo ids='HP_0002625'>deep vein thrombosis</z:hpo> and one <z:hpo ids='HP_0002204'>pulmonary embolism</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Patients with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> are at high risk of pregnancy loss as well as maternal morbidity, especially thrombo-embolic disease </plain></SENT>
<SENT sid="9" pm="."><plain>A randomised prospective controlled trial is necessary to determine the optimum therapy for pregnancy conservation and thrombprophylaxis </plain></SENT>
</text></document>